156 related articles for article (PubMed ID: 23754804)
1. Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program.
Zhang J; Xie F; Delzell E; Chen L; Kilgore ML; Yun H; Saag KG; Lewis JD; Curtis JR
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1743-51. PubMed ID: 23754804
[TBL] [Abstract][Full Text] [Related]
2. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
[TBL] [Abstract][Full Text] [Related]
3. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
Yazdany J; Tonner C; Schmajuk G
Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
[TBL] [Abstract][Full Text] [Related]
4. Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.
Doshi JA; Hu T; Li P; Pettit AR; Yu X; Blum M
Arthritis Care Res (Hoboken); 2016 Nov; 68(11):1624-1630. PubMed ID: 27014854
[TBL] [Abstract][Full Text] [Related]
5. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
6. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.
Yun H; Xie F; Beyl RN; Chen L; Lewis JD; Saag KG; Curtis JR
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1526-1534. PubMed ID: 27813327
[TBL] [Abstract][Full Text] [Related]
7. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
8. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
9. Time trends in medication use and expenditures in older patients with rheumatoid arthritis.
Harrold LR; Peterson D; Beard AJ; Gurwitz JH; Briesacher BA
Am J Med; 2012 Sep; 125(9):937.e9-15. PubMed ID: 22682794
[TBL] [Abstract][Full Text] [Related]
10. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
Curtis JR; Xie F; Yun H; Saag KG; Chen L; Delzell E
Arthritis Rheumatol; 2015 Jun; 67(6):1456-64. PubMed ID: 25708920
[TBL] [Abstract][Full Text] [Related]
11. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
14. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
15. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
16. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
17. Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis.
Baser O; Ganguli A; Roy S; Xie L; Cifaldi M
Clin Ther; 2015 Jul; 37(7):1454-65. PubMed ID: 25999184
[TBL] [Abstract][Full Text] [Related]
18. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
19. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
20. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]